Paris-based startup charts unusual path through continuation vehicle, sidestepping traditional venture playbook
The money arrived in February, though calling it a traditional funding round would miss the point entirely.
Hublo, the Paris-based healthcare workforce platform, closed €40 million (roughly $47 million) through what's known in private equity circles as a continuation vehicle—a reinvestment structure led by early backer Revaia that lets existing investors stick around after last year's ownership shake-up. It's the kind of financial engineering that's become more common as European tech companies mature beyond the straightforward Series A, B, C progression that venture capital mythologizes.
What makes this notable isn't the size. It's the signal: Hublo is no longer a conventional venture bet. Five Arrows, the private equity arm of Rothschild & Co., acquired a majority stake last July. Acton Capital, which co-led the original 2021 Series A with Revaia, cashed out. The February vehicle essentially allows Revaia—and a mix of European, UK, and American limited partners whose names remain closely held—to maintain exposure without getting squeezed out by the new ownership reality.
When Venture Becomes Something Else
Continuation vehicles occupy an odd space. They're not fresh capital in the startup sense—no primary injection to fuel the next phase of breakneck expansion. Instead, they're structural workarounds that let investors reconfigure their positions when a company's ownership changes hands. Think of it as a financial bridge between venture-backed growth and private equity discipline.
For Hublo, that bridge matters. The company operates a SaaS platform connecting over one million registered caregivers with more than 5,000 healthcare facilities across six countries. Some 22,000 healthcare managers use the system to handle shift replacements, scheduling, and recruitment—processing 663,000 missions monthly, totaling five million hours of healthcare labor. It's operational scale, not aspiration.
And the market they're addressing? Under strain is putting it mildly.
WHO Europe projects a shortfall of roughly 950,000 health workers across the region by 2030, with rising reliance on foreign-trained staff. The European Parliament's estimates run higher—between 1.2 and 4.1 million, depending on which methodologies and definitions you trust. The numbers vary, but the trend doesn't: Europe's healthcare systems are scrambling.
Capital Layering
The Revaia vehicle wasn't Hublo's only recent capital event. In October 2025, the company raised €20 million from Bpifrance, France's state-backed investment bank, through its Equity MidCap fund. That's growth capital with a policy flavor—meant to accelerate expansion into Germany, Spain, Belgium, and Switzerland while funding AI-driven product development.
Both rounds now sit on a cap table that includes the founders, Five Arrows, Revaia, and Bpifrance. It's a coalition of patient capital, which feels appropriate given the nature of healthcare infrastructure plays. You don't flip a workforce management platform to another tech company in 18 months.
Hublo also made two acquisitions in May 2025, folding in Permuteo and Staffea to extend its reach into planning and scheduling. Staffea now operates under the name "Hublo Planning," which suggests consolidation rather than maintaining competing brands.
The Profitability Question
According to mySIH, a French healthcare IT publication, Hublo crossed into profitability by the end of 2024. If accurate—and the company hasn't disputed it publicly—that timing matters. It means Five Arrows bought into a business that had already proven unit economics, not one burning cash in pursuit of market dominance.
With approximately 200 employees and operations spanning public hospitals, private clinics, and medico-social facilities, Hublo seems to be navigating the current European tech climate's central mandate: grow, but efficiently. The days of "growth at all costs" feel distant now, perhaps even quaint.
Market analysts peg the European healthcare staffing sector somewhere between $25 billion and $44 billion through 2033, with compound annual growth rates around 7%. Those are respectable figures, though not the explosive projections that once fueled venture enthusiasm. Healthcare infrastructure is steady work, not moonshots.
What This Signals
The real story may be less about Hublo specifically and more about the evolving lifecycle of European tech companies that reach a certain scale. Not every startup becomes a unicorn. Some become solid businesses serving essential needs, transitioning from venture portfolios to private equity oversight without drama.
Whether Hublo can capture meaningful share in a fragmented, crisis-driven market is now the operational question facing Five Arrows and its co-investors. For Revaia, staying involved through a continuation vehicle suggests conviction that the answer will be yes—or at least, conviction enough to see how the next chapter unfolds.
The capital structures don't lie. Patient money is betting that healthcare staffing platforms, built during a labor crisis, might just outlast the frenzy that once surrounded startups promising to "disrupt" everything in sight. Sometimes infrastructure matters more than disruption.
